Lung Cancer Clinical Trial

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Summary

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one regimen of prior anticancer therapy (second line or later) that must have contained a platinum-based chemotherapy drug.

View Full Description

Full Description

This randomized, two-arm, phase 2, multicenter study will evaluate the safety and efficacy of 5.4 mg/kg and 6.4 mg/kg trastuzumab deruxtecan administered every 3 weeks (Q3W) in participants with HER2-mutated metastatic NSCLC. Each participant is expected to receive approximately 14 months of trastuzumab deruxtecan treatment. The primary endpoint of the study will be confirmed objective response rate (blinded independent central review). Secondary endpoints will include, but not limited to, disease control rate, duration of response, progression-free survival, objective response rate (investigator), overall survival, and safety.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Written informed consent
Men or women ≥18 years, follow local regulatory requirements if the legal age of the consent for study participation is >18 years
Pathologically documented metastatic NSCLC with a known activating HER2 mutation. Note: A HER2 mutation documented only from a liquid biopsy samples cannot be used for enrollment.
Had previous treatment including platinum therapy in the metastatic/locally advanced setting and not amenable to curative surgery or radiation. Participant must have progressed during or after the last treatment regimen or discontinued because of unacceptable toxicity.
Presence of at least 1 measurable lesion confirmed by the blinded Independent Central Review based on RECIST version 1.1
Willing and able to provide an archival tumor tissue sample. A fresh biopsy is required if an archival tumor tissue sample cannot be supplied. Resection and core needle biopsy are acceptable. Fine needle aspirates or cell block are not acceptable.
Eastern Cooperative Oncology Group performance status 0 to 1
Left ventricular ejection fraction ≥ 50% within 28 days before randomization Resection and core needle biopsy are acceptable - Adequate organ function as specified in protocol within 14 days before randomization
Adequate treatment washout period before randomization
Participants of reproductive/childbearing potential agree to use a highly effective form of contraception (or avoid intercourse) during study period and up to 7 months (females) and 4 months (males) after last study dose
Males should not freeze or donate sperm throughout the study period up to at least 4 months after last study dose; females should not donate or retrieve ova for their own use throughout the study period and up to at least 7 months after last study dose
Life expectancy 3 months or more

Exclusion Criteria:

Known driver mutation in the epidermal growth factor receptor (EGFR), BRAF, or MET exon 14 gene or a known anaplastic lymphoma kinase (ALK), ROS1, RET, or NTRK fusion
Medical history of myocardial infarction within 6 months before randomization, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV). Participants with troponin levels above upper limit of normal at screening (as defined by the manufacturer) and without any myocardial infarction (MI)-related symptoms should have a cardiologic consultation before randomization to rule out MI
Corrected QT interval (QTcF) prolongation > 470 msec (females) or >450 msec (males) based on average of the triplicate12-lead electrocardiogram at screening
History of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated
History of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product
History of severe hypersensitivity reactions to other monoclonal antibodies
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
Substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the participant's participation in the clinical study or evaluation of the clinical study results
Known human immunodeficiency virus (HIV) infection
Known active, clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C) such as those with serologic evidence of viral infection within 28 days of Cycle 1, Day 1
Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline
Pregnant, breastfeeding, or planning to become pregnant
Otherwise considered inappropriate for the study by the Investigator
Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg. pulmonary emboli within three months of the study randomization, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.)
Any autoimmune, connective tissue or inflammatory disorders (e.g., Rheumatoid arthritis, Sjogren's, sarcoidosis etc.) where there is documented, or a suspicion of pulmonary involvement at the time of screening
Prior complete pneumonectomy
Had prior treatment with any agent, including an antibody drug conjugate (ADC), containing a chemotherapeutic agent targeting topoisomerase I

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

152

Study ID:

NCT04644237

Recruitment Status:

Active, not recruiting

Sponsor:

Daiichi Sankyo

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 46 Locations for this study

See Locations Near You

University of Colorado Denver - Anschutz Medical Campus
Aurora Colorado, 80045, United States
AdventHealth Orlando
Orlando Florida, 32803, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa Florida, 33612, United States
Norton Cancer Institute
Louisville Kentucky, 40241, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
Henry Ford Cancer Institute/Henry Ford Hospital
Detroit Michigan, 48202, United States
University of Michigan
Detroit Michigan, 48202, United States
Washington University School of Medicine
Saint Louis Missouri, 63110, United States
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States
Virgina Cancer Specialists
Fairfax Virginia, 22031, United States
St John of God Subiaco Hospital
Subiaco , 6008, Australia
Princess Alexandra Hospital
Woolloongabba , 4102, Australia
University Health Network
Toronto , M5G0A, Canada
Centre Leon Berard
Lyon , 69008, France
Assistance Publique Hopitaux de Marseille AP-HM, Hopital NORD
Marseille , 13015, France
Hopital Pontchaillou
Rennes , 35000, France
CHU Nantes
Saint-Herblain , 44800, France
CHU toulouse - hôpital Larrey
Toulouse , 31059, France
Gustav Roussy
Villejuif , 94800, France
Ospedale San Luca
Lucca , 55100, Italy
IRCCS Istituto Europeo di Oncologia
Milano , 20141, Italy
SC Oncologia, AOU Policlinico Modena
Modena , 41124, Italy
Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Strutturadi Oncologia
Napoli , 80131, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Orbassano , 10043, Italy
Humanitas Cancer Center Istituto Clinico Humanitas
Rozzano , 20089, Italy
Aichi Cancer Center Hospital
Chikusa , 464-8, Japan
National Cancer Central Hospital
Chuo Ku , 104-0, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka , 11111, Japan
National Cancer Center Hospital East
Kashiwa , 277-0, Japan
Okayama University Hospital
Okayama , 700-8, Japan
Kindai University Hospital
Ōsaka-sayama , 589-8, Japan
Chungbuk National University Hospital
Chungbuk , 28644, Korea, Republic of
Seoul National University Bundang Hospital
Seongnam , 463-7, Korea, Republic of
Seoul National University Hospital
Seoul , 03080, Korea, Republic of
Asan Medical Center
Seoul , 3080, Korea, Republic of
Samsung Medical Center
Seoul , 6351, Korea, Republic of
Netherlands Cancer Institute
Amsterdam , 1066C, Netherlands
Erasmus MC
Rotterdam , 3015 , Netherlands
Hospital Universitario Vall d'Hebron
Barcelona , 08023, Spain
Clinica Universidad de Navarra
Madrid , 28027, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid , 28040, Spain
Hospital 12 de Octubre
Madrid , 28041, Spain
Hospital Universitari i Politècnic La Fe
Valencia , 46026, Spain
Chung Shan Medical University Hospital
Taichung , 40705, Taiwan
Taichung Veterans General Hospital
Taichung , 40705, Taiwan
National Cheng Kung University Hospital NCKUH
Tainan , 704, Taiwan
National Taiwan University Hospital
Taipei City , 10002, Taiwan
Chang Gung Memorial Hospital CGMH - LinKou Branch
Taoyuan , 333, Taiwan

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

152

Study ID:

NCT04644237

Recruitment Status:

Active, not recruiting

Sponsor:


Daiichi Sankyo

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.